Solana Company (NASDAQ: HSDT), formerly Helius Medical Technologies, said it continues to acquire Solana as part of a digital asset treasury (DAT) program and now holds more than 2.2 million SOL, alongside over $15 million in cash earmarked to expand the strategy, according to an Oct. 6 press release. At a reference price of $232.50 per SOL as of 12:00 AM ET on Oct. 6, the firm stated that the combined value of SOL and cash exceeds $525 million, surpassing the gross proceeds from its private placement tha ...

Core Insights - Solana Company, formerly Helius Medical Technologies, is significantly investing in Solana, amassing a treasury of $530 million, which positions it as a major player in the digital asset space [1][2][11] - The strategy is framed as a pivot towards digital assets, aiming to maximize shareholder value by accumulating Solana tokens [4][11] - Rising institutional demand, particularly in Asia, is driving the adoption of Solana, with several public companies announcing similar treasury strategies [5][6] Company Strategy - The company has accumulated over 2.2 million Solana tokens, reflecting a strategic shift towards digital assets [2][4] - Executives are drawing parallels to other notable figures in the crypto space, indicating a broader trend among corporations to invest in digital currencies [4][11] - The treasury's size makes Solana Company one of the largest non-crypto-native holders of SOL, rivaling dedicated funds [11] Market Context - The timing of this investment coincides with increasing institutional interest in Solana and potential U.S. regulatory approvals for Solana ETFs [6][12] - Other companies, such as Forward Industries, are also making substantial commitments to Solana, indicating a growing trend among public companies [5][6] - Technical analysis shows that Solana Company's stock is attempting to stabilize after a downtrend, with key price levels indicating potential breakout points [9][10]

Core Insights - Helius Medical Technologies, Inc. has announced the acquisition of over 2.2 million Solana (SOL) tokens as part of its digital asset treasury strategy, with cash holdings exceeding $15 million, bringing the total value of its combined holdings to over $525 million [1][2][8] Group 1: Company Strategy - The company is committed to its Solana treasury strategy, reflecting long-term confidence in the Solana ecosystem [2] - HSDT's strategy is focused on maximizing shareholder value through efficient accumulation of Solana tokens, with current holdings exceeding the initial capital raise amount in less than three weeks [3] - The company aims to support the growth and security of tokenized networks by being a long-term holder of SOL while continuing its neurotech and medical device operations [5][8] Group 2: Market Position and Performance - Solana is recognized as the fastest growing blockchain, leading in transaction revenue and processing over 3,500 transactions per second, with an average of 3.7 million daily active wallets [5] - The Solana network has surpassed 23 billion transactions year to date and offers a ~7% native staking yield, making it financially productive compared to non-yield-bearing assets like Bitcoin [5] - There is strong interest from institutional investors, particularly from Asia, following recent digital asset conferences, indicating a growing market presence for HSDT [4]

Core Viewpoint - HSDT has rebranded itself as Solana Company, emphasizing its commitment to the Solana blockchain and its mission to maximize SOL per share while providing consistent on-chain yield for investors [1][5][6] Group 1: Corporate Changes - HSDT has filed an amendment to its Certificate of Incorporation to change its name to "Solana Company," while retaining the ticker symbol HSDT [1] - The company has entered into a non-binding letter of intent with the Solana Foundation, committing to conduct all on-chain activities solely on Solana and participate in joint initiatives [2] Group 2: Strategic Initiatives - HSDT is executing a digital asset treasury strategy focused on accumulating SOL tokens, leveraging recent financing of $500 million to support this strategy [3][9] - The company aims to provide access to the Solana network and promote its capabilities through co-hosted events and institutional partnerships [2][9] Group 3: Market Position and Performance - Solana is recognized as the fastest growing blockchain, processing over 3,500 transactions per second and averaging about 3.7 million daily active wallets, with over 23 billion transactions year-to-date [7] - The SOL token offers a ~7% native staking yield, distinguishing it from non-yield-bearing assets like Bitcoin [7]

Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device DesignationNEWTOWN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), today announced the filing of its U.S. Food and Drug Administration (FDA) 510(k) submission for the PoNS (Portable Neuromodulation Stimulator) device label expansion seeking an indication for gait and balance deficit in patients with chronic stroke symptoms. The submission was ...

Group 1 - Helius Medical Technologies, Inc. announced a purchase of 760,000 SOL for $175.60 million, leading to an 8.55% increase in after-hours trading [2][5] - The company currently holds over $335 million in cash, which it plans to use for future acquisitions [2] - The acquisition follows a recent $500 million funding from Pantera Capital and Summer Capital, indicating strong interest in digital assets among Wall Street firms [3] Group 2 - Helius Medical's stock has increased by 157% over the last month, despite a 33.61% drop during the regular trading session prior to the announcement [5] - The current price of SOL is $215.95, reflecting a 6.85% decrease in the last 24 hours [4] - Forward Industries Inc. and DeFi Development Corp. are leading the market in digital asset reserves, holding $1.46 billion and $451.39 million respectively [4]

Group 1 - Helius Medical Technologies, Inc. announced a purchase of 760,000 SOL for $175.60 million, initiating its digital asset treasury strategy [2][3] - The stock price increased by over 8% in after-hours trading, recovering from a 33.61% decline during the regular session [2][5] - Helius Medical currently holds over $335 million in cash, which is earmarked for future acquisitions [2] Group 2 - The acquisition follows a recent $500 million funding from Pantera Capital and Summer Capital through a private investment in public equity offering [3] - The cryptocurrency Solana (SOL) has a market cap of $117 billion, with increasing competition among Wall Street firms to add it to their reserves [3] - Helius Medical's stock has surged 157% over the past month, although it currently shows a low growth score in terms of historical earnings and revenue expansion [5]

Core Insights - Several biotech companies experienced significant stock price increases in after-hours trading, driven by clinical updates, strategic shifts, and upcoming catalysts [1] Cassava Sciences (SAVA) - Shares surged 37.1% to $3.18 in after-hours trading, following a regular session close of $2.32, which marked a 1.75% gain [2] - The rally is attributed to renewed interest in the investigational drug simufilam, particularly its potential in treating TSC-related epilepsy, following positive preclinical data [3] - Leadership changes, including the appointment of Dr. Joseph Hulihan as Chief Medical Officer, indicate a strategic pivot in clinical priorities [3] - Future updates on simufilam and the diagnostic candidate SavaDx could serve as near-term catalysts [4] Helius Medical Technologies (HSDT) - Stock rose 15.67% to $18.53 in after-hours trading after a regular session close of $16.02, where it had dropped 33.61% [4] - The rebound followed a $500 million private placement announcement, marking a significant pivot from its core neurotech focus [5] - Helius continues to advance its medical device pipeline, with positive results from the Portable Neuromodulation Stimulator (PoNS) stroke registrational program and plans for FDA submission [6] Werewolf Therapeutics (HOWL) - Shares increased 9.78% to $2.02 in after-hours trading, following a regular session close of $1.84, which was up 23.49% [6] - The company is advancing multiple conditionally activated cytokine therapies through its INDUKINE platform, with lead candidate WTX-124 in a Phase 1/1b trial targeting advanced solid tumors [7] - Participation in the H.C. Wainwright 27th Annual Global Investment Conference highlighted management's timelines for clinical readouts and pipeline progress [8] Aytu BioPharma Inc. (AYTU) - Stock rose 7.63% to $2.68 in after-hours trading after closing at $2.49, up 2.05% [8] - The price action follows the announcement of full-year and Q4 fiscal 2025 results expected on September 23, 2025, which will clarify commercial performance and progress with EXXUA [9] - Aytu maintains a portfolio of pediatric and ADHD-focused therapeutics and has extended its loan agreement with Eclipse to boost liquidity [10] Equillium Inc. (EQ) - Shares increased 10.34% to $1.60 in after-hours trading after closing at $1.45, down 0.68% [10] - The company announced up to $50 million in financing to advance EQ504 into clinical development, with positive feedback from the FDA regarding its regulatory pathway [11] - Its lead candidate, itolizumab (EQ001), is in Phase 3 trials for acute graft-versus-host disease and has completed earlier-stage studies in lupus nephritis and ulcerative colitis [11]

Core Insights - Helius Medical Technologies' shares dropped 16% following the announcement of its first Solana treasury acquisition, which involved purchasing 760,190 SOL at an average price of $231, valuing the treasury at approximately $168 million [1] - The company has raised $500 million through an oversubscribed private placement to initiate its treasury operations, indicating strong support from stakeholders in the Solana ecosystem [2] - Despite the initial surge in share price, Helius' stock has seen fluctuations, currently trading at $20.19, which is still a 218% increase over the past month [3] Group 1 - Helius Medical Technologies acquired 760,190 SOL at an average price of $231, valuing its treasury at around $168 million [1] - The company maintains approximately $335 million in cash, which will facilitate further acquisitions for its Solana treasury [1] - The firm announced its intention to build a Solana treasury last week, raising $500 million via a private placement led by Pantera Capital and Summer Capital [2] Group 2 - Helius' shares initially surged by 141% to $18.27 but have since fallen to $20.19, despite being up 218% over the last month [3] - The strategy of accumulating SOL at a lower cost basis while retaining capital for opportunistic purchases reflects the company's focus on maximizing shareholder value [4] - Solana's price has dropped around 6.9% in the last 24 hours, trading at $221.19, which is below Helius' average purchase price [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - AgriFORCE Growing Systems Ltd. (AGRI) has increased by 263% to $8.73 [3] - Qualigen Therapeutics, Inc. (QLGN) has risen by 212% to $8.87 [3] - Flora Growth Corp. (FLGC) is up 103% at $55.36 [3] - Boxlight Corporation (BOXL) has gained 102% to $3.16 [3] - Platinum Analytics Cayman Limited (PLTS) is up 96% at $14.00 [3] - Metsera, Inc. (MTSR) has increased by 59% to $52.99 [3] - Anywhere Real Estate Inc. (HOUS) is up 51% at $10.72 [3] - Fold Holdings, Inc. (FLD) has risen by 30% to $5.93 [3] - ARB IOT Group Limited (ARBB) is up 28% at $8.02 [3] - MBX Biosciences, Inc. (MBX) has increased by 26% to $12.64 [3] Premarket Losers - AlphaVest Acquisition Corp (ATMV) has decreased by 27% to $15.99 [4] - Helius Medical Technologies, Inc. (HSDT) is down 17% at $20.00 [4] - CEA Industries Inc. (BNC) has fallen by 15% to $8.20 [4] - Simpple Ltd. (SPPL) is down 13% at $5.00 [4] - FatPipe, Inc. (FATN) has decreased by 11% to $7.87 [4] - Tharimmune, Inc. (THAR) is down 11% at $3.20 [4] - Yueda Digital Holding (YDKG) has fallen by 11% to $2.98 [4] - American Battery Technology Company (ABAT) is down 10% at $2.94 [4] - AGM Group Holdings Inc. (AGMH) has decreased by 9% to $9.36 [4] - Antelope Enterprise Holdings Limited (AEHL) is down 5% at $3.38 [4]